Prostate Cancer Clinical Trials in Arizona

Showing 181-200 of 287 trials

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

NCT02987829

This is a multi-center, first-in-human, open-label, Phase 1/2A dose-escalation study in which eligible patients with metastatic castration-resistant prostate carcinoma (mCRPC) will receive oral doses of TRC253. The study will be conducted in 2 parts: part 1 (dose escalation) and part 2 (dose expansion).

Metastatic Castrate-resistant Prostate CancerAdenocarcinoma, Prostate

Tracon Pharmaceuticals Inc.72 participantsStarted May 2017

Birmingham, Alabama, United States • Scottsdale, Arizona, United States • Santa Monica, California, United States +2 more locations

TERMINATEDPhase 1/231 miles

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

NCT02709889

The primary objective of this study is to assess the safety and tolerability of rovalpituzumab tesirine in subjects with specific delta-like protein 3-expressing advanced solid tumors.

Malignant MelanomaMedullary Thyroid CancerGlioblastoma+5 more

AbbVie200 participantsStarted Sep 2016

Gilbert, Arizona, United States • Scottsdale, Arizona, United States • Los Angeles, California, United States +27 more locations

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Prostate Cancer Trials in Other Cities

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer

Genetic Analysis of Hereditary Prostate Cancer

Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers

Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer

Phase 2 Trial of Enzastaurin in Prostate Cancer in Participants Who Have Had Hormonal and Chemotherapy

ARMOR1: Study of TOK-001 to Treat Castration Resistant Prostate Cancer

Study of the Effect of GTx-758 on Serum PSA and Testosterone in Men With Prostate Cancer

TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

Clinical Outcomes in Men With Prostate Cancer Who Selected Active Surveillance Using Prolaris® Testing

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Prostate Cancer Localization With a Multiparametric Magnetic Resonance (MR) Approach

A Registry for Hereditary Cancer Risk Assessment and Genetic Testing

Carboplatin Plus Docetaxel (Taxotere) in Anaplastic Prostate Cancer

Other Conditions in Arizona